您是第 11111358 位 欢迎访问 中乔新舟官网 ! 全国免费电话:400-038-9959 我的购物车(0) 注 册 / 登 录
扫码关注公众号
您当前的位置:首页 > 产品中心

Panc02.03人胰腺腺癌细胞

英文名:Panc02.03
货号:ZQ1189
价格:¥询价
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

Panc02.03人胰腺腺癌细胞

货号

ZQ1189

产品介绍

Panc 02.03(CRL-2553™)是一种人类胰腺腺癌细胞系,该细胞系于1995年从一个患有腺癌的70岁白人女性患者的胰腺中分离出来。Panc 02.03细胞系在癌症研究中通常有以下应用:基础癌症生物学研究、药物筛选和测试、肿瘤微环境研究、基因和蛋白质表达分析、细胞凋亡和存活研究、肿瘤形成和转移研究、3D细胞培养、
免疫学研究、耐药性研究、癌症干细胞研究等。因其保留了原始肿瘤的许多特性,因此在胰腺癌的研究中非常有用,尤其是在探索疾病机制和评估新疗法方面。

种属

性别/年龄

女/70

组织

胰腺

疾病

胰腺腺癌

细胞类型

肿瘤细胞细胞系

形态学

上皮细胞样

生长方式

贴壁

倍增时间

~28.2 hours (PubMed=9612602).

培养基和添加剂

RPMI-1640(品牌:中乔新舟 货号:ZQ-200 +15%胎牛血清(中乔新舟  货号:ZQ500-A+1%P/S(中乔新舟  货号:CSP006+10ug/ml Insulin(中乔新舟  货号:CSP001-10

推荐完全培养基货号

ZM1189

生物安全等级

BSL-1

培养条件

95%空气,5%二氧化碳;37℃

STR位点信息

Amelogenin: X
D3S1358: 14
TH01: 6
D21S11: 28,31
D18S51: 14
Penta_E: 5,7
D5S818: 12,13
D13S317: 12
D7S820: 9,10
D16S539: 11
CSF1PO: 11,12
Penta_D: 9
vWA: 17
D8S1179: 11,12
TPOX: 9,12
FGA: 20,21
D19S433: 13,16
D2S1338: 19,20

抗原表达/受体表达

*** 

基因表达

*** 

保藏机构

ATCC; CRL-2553

供应限制

仅供科研使用

货号

ZQ1189

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用

PubMed=9612602
Jaffee E.M., Schutte M., Gossett J., Morsberger L.A., Adler A.J., Thomas M., Greten T.F., Hruban R.H., Yeo C.J., Griffin C.A.
Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials.
Cancer J. Sci. Am. 4:194-203(1998)


PubMed=18000365; DOI=10.1159/000108295
Griffin C.A., Morsberger L.A., Hawkins A.L., Haddadin M.H., Patel A.S., Ried T., Schrock E., Perlman E.J., Jaffee E.M.
Molecular cytogenetic characterization of pancreas cancer cell lines reveals high complexity chromosomal alterations.
Cytogenet. Genome Res. 118:148-156(2007)


PubMed=20037478; DOI=10.4161/cbt.8.21.9685; PMCID=PMC2824894
Kent O.A., Mullendore M.E., Wentzel E.A., Lopez-Romero P., Tan A.-C., Alvarez H., West K.M., Ochs M.F., Hidalgo M., Arking D.E., Maitra A., Mendell J.T.
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.
Cancer Biol. Ther. 8:2013-2024(2009)


PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)


PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)


PubMed=25167228; DOI=10.1038/bjc.2014.475; PMCID=PMC4453732
Hamidi H., Lu M., Chau K., Anderson L., Fejzo M.S., Ginther C., Linnartz R., Zubel A., Slamon D.J., Finn R.S.
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
Br. J. Cancer 111:1788-1801(2014)


PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)


PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)


PubMed=26216984; DOI=10.1073/pnas.1501605112; PMCID=PMC4538616
Daemen A., Peterson D., Sahu N., McCord R., Du X.-N., Liu B., Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R., Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.L., Manning G., Settleman J., Hatzivassiliou G., Evangelista M.
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015)


PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)


PubMed=27259358; DOI=10.1074/mcp.M116.058313; PMCID=PMC4974343
Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M., Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K., Biankin A.V., Wu J.-M., Daly R.J.
Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.
Mol. Cell. Proteomics 15:2671-2685(2016)


PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)


PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)


PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051; PMCID=PMC6343826
Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.
Differential effector engagement by oncogenic KRAS.
Cell Rep. 22:1889-1902(2018)


PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)


PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)


PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)


PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)


PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

暂无相关产品!
公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
      上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经十多年发展,...
联系我们 / Contact
电 话:021-56760357;021-56760351
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved. 网站地图

沪公网安备 31011002001038号

技术支持:攸攸网络 沪ICP备14008091号